Fig. 4
From: Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
The proportions of clinical trials on CAR-T cell therapy targets in hematological malignancies. NHL: non-Hodgkin’s lymphoma; TRBC: T cell receptor β-chain constant domains; HL: Hodgkin’s lymphoma; B-ALL: B-acute lymphoblastic leukemia; BAFF-R: B-cell activating factor receptor; TSLPR: thymic stromal lymphopoietin receptor; T-ALL: T-acute lymphoblastic leukemia; AML: acute myeloid leukemia; WT1: wilms tumor 1; FLT3: FMS-like tyrosine kinase 3; NKG2DL: natural killer group 2 member D ligand; CLL1: C-type lectin like molecule 1; CLL: chronic lymphocytic leukemia; BCMA: B-cell maturation antigen; ROR: receptor tyrosine kinase like orphan receptor; MM: multiple myeloma; SLAMF7: signaling lymphocytic activation molecule F7; GPRC5D: G protein-coupled receptor class-C group-5 member-D